CR20160564A - Dinucleótidos cíclicos como moduladores de sting - Google Patents

Dinucleótidos cíclicos como moduladores de sting

Info

Publication number
CR20160564A
CR20160564A CR20160564A CR20160564A CR20160564A CR 20160564 A CR20160564 A CR 20160564A CR 20160564 A CR20160564 A CR 20160564A CR 20160564 A CR20160564 A CR 20160564A CR 20160564 A CR20160564 A CR 20160564A
Authority
CR
Costa Rica
Prior art keywords
cyclic dinucleotides
sting modulators
sting
modulators
dinucleotides
Prior art date
Application number
CR20160564A
Other languages
English (en)
Spanish (es)
Inventor
Keith Biggadike
Aurelie Cecile Champigny
Diane Mary Coe
Daniel Terence Tape
Deborah Needham
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201409911A external-priority patent/GB201409911D0/en
Priority claimed from GB201501466A external-priority patent/GB201501466D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CR20160564A publication Critical patent/CR20160564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20160564A 2014-06-04 2015-06-02 Dinucleótidos cíclicos como moduladores de sting CR20160564A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201409911A GB201409911D0 (en) 2014-06-04 2014-06-04 Novel compounds
GB201501466A GB201501466D0 (en) 2015-01-29 2015-01-29 Novel compounds
PCT/EP2015/062281 WO2015185565A1 (en) 2014-06-04 2015-06-02 Cyclic di-nucleotides as modulators of sting

Publications (1)

Publication Number Publication Date
CR20160564A true CR20160564A (es) 2017-01-20

Family

ID=53398059

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160564A CR20160564A (es) 2014-06-04 2015-06-02 Dinucleótidos cíclicos como moduladores de sting

Country Status (18)

Country Link
US (1) US10450341B2 (enExample)
EP (1) EP3152217B1 (enExample)
JP (1) JP6462006B2 (enExample)
KR (1) KR20170015353A (enExample)
CN (1) CN106459131B (enExample)
AU (1) AU2015270640B2 (enExample)
CA (1) CA2950033A1 (enExample)
CL (1) CL2016003056A1 (enExample)
CR (1) CR20160564A (enExample)
DO (1) DOP2016000316A (enExample)
EA (1) EA029856B9 (enExample)
ES (1) ES2692226T3 (enExample)
IL (1) IL248604A0 (enExample)
MX (1) MX2016015928A (enExample)
PE (1) PE20170198A1 (enExample)
PH (1) PH12016502318A1 (enExample)
SG (1) SG11201609021QA (enExample)
WO (1) WO2015185565A1 (enExample)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
IL280430B2 (en) * 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) * 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CA3029644A1 (en) * 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US10537590B2 (en) * 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＳＴＩＮＧアゴニストとしてのベンゾ［ｂ］チオフェン化合物
WO2018065360A1 (de) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
ES2924186T3 (es) * 2017-01-27 2022-10-05 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de STING
ES2891326T3 (es) 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
CA3053568A1 (en) 2017-02-21 2018-08-30 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
EA036435B1 (ru) * 2017-02-22 2020-11-10 Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед Гетероциклические амиды, пригодные в качестве модуляторов белков
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
WO2018198084A1 (en) * 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11969499B2 (en) 2017-06-16 2024-04-30 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment cancer
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
TWI808092B (zh) 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
EP3676277A1 (en) * 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
CA3078309A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Methods for administering sting agonists
AU2018344902B2 (en) * 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CN109694397B (zh) * 2017-10-23 2021-08-31 上海弘翊生物科技有限公司 环状二核苷酸化合物、其制备方法和应用
PH12020550585A1 (en) * 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
CN110016021B (zh) * 2018-01-08 2021-05-07 成都先导药物开发股份有限公司 一种免疫调节剂
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
US10519187B2 (en) * 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3755331B1 (en) 2018-02-21 2026-01-28 The Scripps Research Institute Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TW202003032A (zh) 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 包含ｓ ｔ ｉ ｎ ｇ 促效劑之胞外囊泡
EP3768685A1 (en) * 2018-03-23 2021-01-27 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
WO2019185477A1 (en) 2018-03-27 2019-10-03 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
US20210024567A1 (en) 2018-03-27 2021-01-28 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
TWI833744B (zh) * 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3802534B1 (en) 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US12251394B2 (en) 2018-06-01 2025-03-18 Eisai R&D Management Co., Ltd. Methods for the treatment of bladder cancer
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
KR102783784B1 (ko) 2018-08-16 2025-03-21 에자이 알앤드디 매니지먼트 가부시키가이샤 화합물의 염 및 이의 결정
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
CN118846110A (zh) 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物
MA53659A (fr) * 2018-09-21 2022-02-23 Shanghai De Novo Pharmatech Co Ltd Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
EP3873484B1 (en) 2018-10-29 2023-08-23 Venenum Biodesign, LLC Novel sting agonists
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
CN113574063B (zh) * 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
CN114127082A (zh) * 2019-05-09 2022-03-01 阿里戈斯治疗公司 作为sting调节剂的经修饰的环状二核苷化合物
TWI925817B (zh) 2019-05-10 2026-05-21 日商武田藥品工業股份有限公司 抗體藥物結合物
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
DK4004002T3 (da) * 2019-07-22 2024-09-30 Lupin Ltd Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed
EP4003325A1 (en) * 2019-07-24 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN110590888B (zh) * 2019-09-10 2022-10-28 山东大学 一种应用sting蛋白亲合纯化环二核苷酸的方法
CN114727947A (zh) 2019-09-25 2022-07-08 科迪亚克生物科学公司 细胞外囊泡组合物
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ， インコーポレイテッド 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US20230074558A1 (en) 2019-12-06 2023-03-09 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
US12678512B2 (en) 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
CN116196435B (zh) 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
IL298019A (en) 2020-05-13 2023-01-01 Massachusetts Inst Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN111956797B (zh) * 2020-07-10 2022-05-13 清华大学 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
EP4209506A4 (en) 2020-09-02 2024-10-09 Daiichi Sankyo Company, Limited NEW ENDO-N-ACETYL GLUCOSAMINIDASE
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
EP4262878A1 (en) 2020-12-17 2023-10-25 Trustees Of Tufts College Fap-activated radiotheranostics, and uses related thereto
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
JP2024514707A (ja) 2021-04-20 2024-04-02 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
JP2024517131A (ja) 2021-04-20 2024-04-19 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof
WO2025262266A1 (en) 2024-06-21 2025-12-26 Institut National de la Santé et de la Recherche Médicale Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
EP1645561A1 (en) 2003-07-15 2006-04-12 Mitsui Chemicals, Inc. Method of synthesizing cyclic bisdinucleoside
JP2007500697A (ja) 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
US20050187278A1 (en) 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
AU2013256468A1 (en) 2012-04-30 2014-12-04 Glen N. Barber Modulating immune responses
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US20140170689A1 (en) 2012-12-12 2014-06-19 The Research Foundation For The State University Of New York Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
EP3071229A4 (en) * 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
WO2015187009A1 (en) 2014-06-02 2015-12-10 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
EP3233191A1 (en) 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP3233089A4 (en) 2014-12-17 2018-11-14 Lipogen LLC Method of treating cancer with cgamp or cgasmp
WO2016115480A1 (en) 2015-01-16 2016-07-21 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
EP3256608A4 (en) 2015-02-13 2019-02-20 Icahn School of Medicine at Mount Sinai RNA CONTAINING COMPOSITIONS AND METHODS OF USE
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법

Also Published As

Publication number Publication date
PH12016502318A1 (en) 2017-02-06
EA029856B9 (ru) 2018-08-31
EP3152217B1 (en) 2018-08-01
US20180186828A1 (en) 2018-07-05
IL248604A0 (en) 2016-12-29
WO2015185565A1 (en) 2015-12-10
CN106459131B (zh) 2019-04-12
JP2017518302A (ja) 2017-07-06
EP3152217A1 (en) 2017-04-12
SG11201609021QA (en) 2016-11-29
AU2015270640A1 (en) 2016-12-01
EA029856B1 (ru) 2018-05-31
MX2016015928A (es) 2017-03-20
DOP2016000316A (es) 2017-03-31
AU2015270640B2 (en) 2017-10-26
CN106459131A (zh) 2017-02-22
CL2016003056A1 (es) 2017-05-05
JP6462006B2 (ja) 2019-01-30
CA2950033A1 (en) 2015-12-10
EA201692119A1 (ru) 2017-06-30
PE20170198A1 (es) 2017-04-08
US10450341B2 (en) 2019-10-22
ES2692226T3 (es) 2018-11-30
KR20170015353A (ko) 2017-02-08

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12017501191B1 (en) Quinazoline derivatives used to treat hiv
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
MX2017017008A (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
ECSP16096831A (es) Derivados de naftiridinadiona
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ